Skip to main content

Updates on treating ductal carcinoma in situ: what's to know in 2021.

Publication ,  Journal Article
Haji, F; Baker, JL; DiNome, ML
Published in: Curr Opin Obstet Gynecol
February 1, 2022

PURPOSE OF REVIEW: Ductal carcinoma in situ (DCIS) is a noninvasive stage of disease but understood to be a nonobligate precursor to invasive breast cancer. As such, women with DCIS are routinely recommended for standard breast cancer treatment to prevent progression to invasive disease. DCIS, however, represents a heterogeneous group of lesions that differs in its biologic behavior and risk of progression. Thus, optimal treatment is unclear. This review presents the clinical trials evaluating the de-escalation of therapy, attempts at risk stratification, and future directions in the management of this disease. RECENT FINDINGS: The de-escalation of therapy for patients with DCIS is being actively explored. Although no group of patients based on clinicopathologic features has yet been identified as suitable for omission of therapy, molecular tests appear better able to stratify patients at low risk for whom omission of radiation may be considered. Trials considering omission of surgery are ongoing, and the use of Herceptin and vaccine therapy are also being explored. SUMMARY: The current review provides a centralized summary enabling the clinician to better understand the complexity of DCIS and the controversies over the optimal management of this disease. It highlights the need for better risk stratification to individualize patient care. VIDEO ABSTRACT: http://links.lww.com/COOG/A77.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Curr Opin Obstet Gynecol

DOI

EISSN

1473-656X

Publication Date

February 1, 2022

Volume

34

Issue

1

Start / End Page

46 / 51

Location

England

Related Subject Headings

  • Obstetrics & Reproductive Medicine
  • Humans
  • Female
  • Carcinoma, Intraductal, Noninfiltrating
  • Carcinoma, Ductal, Breast
  • Breast Neoplasms
  • 3215 Reproductive medicine
  • 1114 Paediatrics and Reproductive Medicine
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Haji, F., Baker, J. L., & DiNome, M. L. (2022). Updates on treating ductal carcinoma in situ: what's to know in 2021. Curr Opin Obstet Gynecol, 34(1), 46–51. https://doi.org/10.1097/GCO.0000000000000753
Haji, Farnaz, Jennifer L. Baker, and Maggie L. DiNome. “Updates on treating ductal carcinoma in situ: what's to know in 2021.Curr Opin Obstet Gynecol 34, no. 1 (February 1, 2022): 46–51. https://doi.org/10.1097/GCO.0000000000000753.
Haji F, Baker JL, DiNome ML. Updates on treating ductal carcinoma in situ: what's to know in 2021. Curr Opin Obstet Gynecol. 2022 Feb 1;34(1):46–51.
Haji, Farnaz, et al. “Updates on treating ductal carcinoma in situ: what's to know in 2021.Curr Opin Obstet Gynecol, vol. 34, no. 1, Feb. 2022, pp. 46–51. Pubmed, doi:10.1097/GCO.0000000000000753.
Haji F, Baker JL, DiNome ML. Updates on treating ductal carcinoma in situ: what's to know in 2021. Curr Opin Obstet Gynecol. 2022 Feb 1;34(1):46–51.

Published In

Curr Opin Obstet Gynecol

DOI

EISSN

1473-656X

Publication Date

February 1, 2022

Volume

34

Issue

1

Start / End Page

46 / 51

Location

England

Related Subject Headings

  • Obstetrics & Reproductive Medicine
  • Humans
  • Female
  • Carcinoma, Intraductal, Noninfiltrating
  • Carcinoma, Ductal, Breast
  • Breast Neoplasms
  • 3215 Reproductive medicine
  • 1114 Paediatrics and Reproductive Medicine